蔗糖铁注射液辅助治疗肾衰患者肾性贫血疗较分析(1)
doi：10.3969/j.issn.1007-614x.2014.3.26
摘 要 目的：探讨静脉应用蔗糖铁辅助治疗慢性肾衰患者肾性贫血的有效性与安全性。方法：选择维持性血液透析治疗合并有肾性贫血的患者26例，随机分为两组：静脉应用蔗糖铁治疗组(A组，n=13)，静脉应用100mg蔗糖铁稀释于100ml生理盐水中，于每次透析2小时后静脉滴注；口服琥珀酸亚铁治疗组(B组，n=13)，琥珀酸亚铁200mg/次，口服，3次/日。两组均同时联合使用促红细胞生成素(EPO)治疗，剂量100～150U/(kg·周)，分两次于透析结束时静注。对比观察两组治疗后4、8、12周血红蛋白(Hb)、红细胞压积(Hct)、铁蛋白(SF)和转铁蛋白饱和度(TSAT)4项指标的变化及不良反应的发生情况。结果：静脉应用蔗糖铁辅助治疗慢性肾衰患者肾性贫血效果确切(治疗前后比较，P<0.01)。静脉组治疗后Hb、Hct、SF、TSAT均明显高于口服组(组间比较，P<0.01)。口服组发生不良反应5例(38.4%)，静脉组无不良反应发生，组间差异有统计学意义P<0.01)。结论：静脉应用蔗糖铁联合重组人促红细胞生成素(EPO)治疗慢性肾衰患者肾性贫血疗效确切，较口服补铁能更快、更好地改善肾性贫血(P<0.01)，且不良反应发生率低。
关键词 蔗糖铁注射液 红细胞生成素 肾性贫血 血液透析
Efficacy analysis of Iron sucrose injection as adjuvant therapy in renal anemia of renal failure patients
Tang Xiuhong1，Zhang Jun2
Department of internal medicine， Baoshan hospital of Ping Zhuang Zhen of Chifeng City，Inner Mongolia，0240761
Pingzhuang Mine General Hospital of Chifeng City，Inner Mongolia2
Abstract Objective：To explore the safety and effectiveness of Iron Sucrose Injection adjuvant therapy of renal anemia in patients with renal failure.Methods：We selected 26 cases of patients treated with maintenance hemodialysis with renal anemia， randomly divided into two groups：Intravenous iron sucrose treatment group(group A，n=13)，intravenous iron sucrose 100mg diluted in 100ml saline，intravenous drip in two hours after each dialysis；Oral ferrous succinate group(group B，n=13)，ferrous succinate200mg/time，three times a day orally.The two groups were combined with erythropoietin(EPO) therapy，dose of 100～150U/(kg·week)，intravenous drip after the end of hemodialysis，intravenous injection in two times after dialysis.we observed the changes of hemoglobin(Hb)，hematocrit(Hct)，serum ferritin(SF)and transferrin saturation(TSAT)and the incidence of adverse reactions in the two groups.Results：The effect of intravenous iron sucrose as auxiliary treatment of renal anemia of chronic renal failure anemia patients was significant(before and after treatment，P<0.01).After treatment，Hb，Hct，SF and TSAT in vein group were significantly higher than the oral group(groups，P<0.01).The adverse reactions in oral group occurred in 5 cases(38.4%)，and intravenous group had no adverse reactions.The difference between the two groups was significant(P<0.01).Conclusion：The effect of Iron Sucrose Injection as adjuvant therapy combined with recombinant human erythropoietin in renal failure patients with renal anemia was significant.It can faster and better improve renal anemia compared with oral iron supplementation(P<0.01)，and had low incidence rate of adverse reactions., 百拇医药(唐秀红 张军)
摘 要 目的：探讨静脉应用蔗糖铁辅助治疗慢性肾衰患者肾性贫血的有效性与安全性。方法：选择维持性血液透析治疗合并有肾性贫血的患者26例，随机分为两组：静脉应用蔗糖铁治疗组(A组，n=13)，静脉应用100mg蔗糖铁稀释于100ml生理盐水中，于每次透析2小时后静脉滴注；口服琥珀酸亚铁治疗组(B组，n=13)，琥珀酸亚铁200mg/次，口服，3次/日。两组均同时联合使用促红细胞生成素(EPO)治疗，剂量100～150U/(kg·周)，分两次于透析结束时静注。对比观察两组治疗后4、8、12周血红蛋白(Hb)、红细胞压积(Hct)、铁蛋白(SF)和转铁蛋白饱和度(TSAT)4项指标的变化及不良反应的发生情况。结果：静脉应用蔗糖铁辅助治疗慢性肾衰患者肾性贫血效果确切(治疗前后比较，P<0.01)。静脉组治疗后Hb、Hct、SF、TSAT均明显高于口服组(组间比较，P<0.01)。口服组发生不良反应5例(38.4%)，静脉组无不良反应发生，组间差异有统计学意义P<0.01)。结论：静脉应用蔗糖铁联合重组人促红细胞生成素(EPO)治疗慢性肾衰患者肾性贫血疗效确切，较口服补铁能更快、更好地改善肾性贫血(P<0.01)，且不良反应发生率低。
关键词 蔗糖铁注射液 红细胞生成素 肾性贫血 血液透析
Efficacy analysis of Iron sucrose injection as adjuvant therapy in renal anemia of renal failure patients
Tang Xiuhong1，Zhang Jun2
Department of internal medicine， Baoshan hospital of Ping Zhuang Zhen of Chifeng City，Inner Mongolia，0240761
Pingzhuang Mine General Hospital of Chifeng City，Inner Mongolia2
Abstract Objective：To explore the safety and effectiveness of Iron Sucrose Injection adjuvant therapy of renal anemia in patients with renal failure.Methods：We selected 26 cases of patients treated with maintenance hemodialysis with renal anemia， randomly divided into two groups：Intravenous iron sucrose treatment group(group A，n=13)，intravenous iron sucrose 100mg diluted in 100ml saline，intravenous drip in two hours after each dialysis；Oral ferrous succinate group(group B，n=13)，ferrous succinate200mg/time，three times a day orally.The two groups were combined with erythropoietin(EPO) therapy，dose of 100～150U/(kg·week)，intravenous drip after the end of hemodialysis，intravenous injection in two times after dialysis.we observed the changes of hemoglobin(Hb)，hematocrit(Hct)，serum ferritin(SF)and transferrin saturation(TSAT)and the incidence of adverse reactions in the two groups.Results：The effect of intravenous iron sucrose as auxiliary treatment of renal anemia of chronic renal failure anemia patients was significant(before and after treatment，P<0.01).After treatment，Hb，Hct，SF and TSAT in vein group were significantly higher than the oral group(groups，P<0.01).The adverse reactions in oral group occurred in 5 cases(38.4%)，and intravenous group had no adverse reactions.The difference between the two groups was significant(P<0.01).Conclusion：The effect of Iron Sucrose Injection as adjuvant therapy combined with recombinant human erythropoietin in renal failure patients with renal anemia was significant.It can faster and better improve renal anemia compared with oral iron supplementation(P<0.01)，and had low incidence rate of adverse reactions., 百拇医药(唐秀红 张军)
参见：首页 > 医疗版 > 疾病专题 > 血液内科 > 贫血